サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1612838

感染症の体外診断の世界市場：業界分析、規模、シェア、成長、動向、予測（2024年～2031年）

Infectious Disease In-vitro Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

出版日
ページ情報
英文 188 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
感染症の体外診断の世界市場：業界分析、規模、シェア、成長、動向、予測（2024年～2031年）
出版日: 2024年12月09日
発行: Persistence Market Research
ページ情報: 英文 188 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の感染症の体外診断の市場規模は、2024年に445億米ドルになるとみられ、2024年～2031年の予測期間に4.7%のCAGRで拡大し、2031年には612億米ドルに達すると予測されています。

感染症の体外診断市場とは、細菌、ウイルス、真菌、寄生虫などの病原体によって引き起こされる感染症を検出するために使用される診断検査を指します。これらの診断検査は、感染症の早期発見、管理、治療に不可欠です。この市場を牽引しているのは、世界の感染症流行率の上昇、診断技術の技術的進歩、迅速かつ正確な診断ツールに対するニーズの高まりであり、特に世界のパンデミックの影響を受けています。市場には、分子診断、免疫測定、微生物検査など、さまざまな分野が含まれます。

世界の感染症の体外診断の市場の発展には、特に発展途上地域における感染症罹患率の上昇、ヘルスケアインフラの成長など、いくつかの要因が寄与しています。早期診断に対する意識の高まりや、感染症に対するポイントオブケア検査（POCT）の需要の高まりが、市場の成長をさらに後押ししています。また、COVID-19、結核、HIV、マラリアなどの疾患の発生頻度の増加により、正確で迅速な診断ツールに対するニーズも高まっています。さらに、分子診断と次世代シーケンシング（NGS）の技術的進歩が市場を前進させると予想されます。

感染症の体外診断市場は、特に感染症負担の増加により、より優れた診断ツールへの需要が高まっている新興国において、大きなビジネスチャンスをもたらしています。PCRベースの技術やCRISPRを含む分子診断の進歩は、技術革新と拡大の新たな機会を提供します。さらに、個別化医療への傾向の高まりとマルチプレックス検査プラットフォームの開発は、市場参入企業に成長の道を提供します。さらに、診断企業とヘルスケアプロバイダーとのコラボレーションの増加は、市場拡大の新たな機会を開くと期待されています。

当レポートでは、世界の感染症の体外診断市場について調査し、製品タイプ別、技術別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値の洞察

第4章 世界の感染症の体外診断市場の見通し：実績（2019年～2023年）および予測（2024年～2031年）

  • 主なハイライト
  • 市場規模（10億米ドル）分析と予測
  • 世界の感染症の体外診断市場の見通し：製品タイプ別
  • 市場の魅力分析：製品タイプ別
  • 世界の感染症の体外診断市場の見通し：技術別
  • 市場の魅力分析：技術別
  • 世界の感染症の体外診断市場の見通し：用途別
  • 市場の魅力分析：用途別
  • 世界の感染症の体外診断市場の見通し：エンドユーザー別
  • 市場の魅力分析：エンドユーザー別

第5章 世界の感染症の体外診断市場の見通し：地域別

  • 主なハイライト
  • 過去の市場規模（10億米ドル）分析、地域別、2019年～2023年
  • 現在の市場規模（10億米ドル）の分析と予測、地域別、2024年～2031年
  • 市場の魅力分析：地域別

第6章 北米の感染症の体外診断市場の見通し：実績（2019年～2023年）および予測（2024年～2031年）

第7章 欧州の感染症の体外診断市場の見通し：実績（2019年～2023年）および予測（2024年～2031年）

第8章 東アジアの感染症の体外診断市場の見通し：実績（2019年～2023年）および予測（2024年～2031年）

第9章 南アジアおよびオセアニアの感染症の体外診断市場の見通し：実績（2019年～2023年）および予測（2024年～2031年）

第10章 ラテンアメリカの感染症の体外診断市場の見通し：実績（2019年～2023年）および予測（2024年～2031年）

第11章 中東・アフリカの感染症の体外診断市場の見通し：実績（2019年～2023年）および予測（2024年～2031年）

第12章 競合情勢

  • 市場シェア分析、2023年
  • 市場構造
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • QIAGEN
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc. (Gen Probe)
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.

第13章 付録

目次
Product Code: PMRREP33205

Persistence Market Research has recently released a comprehensive report on the global Infectious Disease In-vitro Diagnostics (IVD) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Infectious Disease In-vitro Diagnostics Market Size (2024E): US$ 44.5 Bn
  • Projected Market Value (2031F): US$ 61.2 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

The Infectious Disease In-vitro Diagnostics market refers to diagnostic tests used for detecting infections caused by pathogens such as bacteria, viruses, fungi, and parasites. These diagnostic tests are essential in the early detection, management, and treatment of infectious diseases. The market is driven by rising global infectious disease prevalence, technological advancements in diagnostic technologies, and an increasing need for rapid and accurate diagnostic tools, especially in the wake of global pandemics. The market encompasses various segments, including molecular diagnostics, immunoassays, and microbiology testing.

Market Growth Drivers:

Several factors are contributing to the growth of the global Infectious Disease IVD market, including the rising incidence of infectious diseases, especially in developing regions, and growing healthcare infrastructure. Increasing awareness about early diagnosis and the growing demand for point-of-care testing (POCT) for infectious diseases are further propelling market growth. The need for accurate and rapid diagnostic tools is also rising due to the increasing frequency of outbreaks of diseases such as COVID-19, tuberculosis, HIV, and malaria. Additionally, technological advancements in molecular diagnostics and next-generation sequencing (NGS) are expected to drive the market forward.

Market Restraints:

Despite its growth potential, the Infectious Disease IVD market faces challenges such as high costs associated with advanced diagnostic tests, particularly in low-income regions. Regulatory hurdles in some countries, along with the need for extensive validation and certification of diagnostic products, may also limit market expansion. Moreover, the lack of awareness in remote areas regarding the availability and benefits of in-vitro diagnostics poses a barrier to the widespread adoption of diagnostic tools.

Market Opportunities:

The Infectious Disease IVD market presents significant opportunities, particularly in emerging economies, where the demand for better diagnostic tools is growing due to the rising burden of infectious diseases. Advancements in molecular diagnostics, including PCR-based technologies and CRISPR, offer new opportunities for innovation and expansion. Further, the increasing trend toward personalized medicine and the development of multiplex testing platforms provide growth avenues for market players. Additionally, the rise in collaborations between diagnostic companies and healthcare providers is expected to open new opportunities for market expansion.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global Infectious Disease IVD market?
  • Which diagnostic technologies and testing platforms are leading the market in terms of demand and revenue?
  • How are advancements in molecular diagnostics and PCR technologies influencing the Infectious Disease IVD market?
  • Who are the leading players in the Infectious Disease IVD market, and what strategies are they employing to maintain their market positions?
  • What are the emerging trends and future prospects in the global Infectious Disease IVD market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Infectious Disease IVD market, such as Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers, are focusing on enhancing their product portfolios, including rapid diagnostics and molecular testing platforms. These companies are investing in innovative technologies such as real-time PCR, next-generation sequencing (NGS), and point-of-care testing solutions. Collaborations with healthcare providers, research institutions, and public health organizations are critical to expanding market reach. Moreover, focusing on regulatory compliance, product differentiation, and technological advancements will help companies maintain a competitive edge and capitalize on the growing demand for efficient and accurate infectious disease diagnostics.

Key Companies Profiled:

  • QIAGEN
  • Becton, Dickinson and Company
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc. (Gen Probe)
  • Abbott
  • Quidel Corporation
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • OraSure Technologies, Inc.

Infectious Disease In-vitro Diagnostics Industry Segmentation

By Product Type

  • Instruments
  • Reagents
  • Software and Services

By Technology

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology

By Application

  • MRSA
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19

By End User

  • Point-of-care
  • Central Laboratories

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Infectious Disease In-Vitro Diagnostics Market Snapshot, 2024 - 2031
  • 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. Parent Market Analysis
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis

4. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
  • 4.3. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019 - 2023
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
      • 4.3.3.1. Instruments
      • 4.3.3.2. Reagents
      • 4.3.3.3. Software and Services
  • 4.4. Market Attractiveness Analysis: Product Type
  • 4.5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Technology
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019 - 2023
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
      • 4.5.3.1. Immunoassay
      • 4.5.3.2. Molecular Diagnostics
      • 4.5.3.3. Microbiology
      • 4.5.3.4. Others
  • 4.6. Market Attractiveness Analysis: Technology
  • 4.7. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Application
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2023
    • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
      • 4.7.3.1. MRSA
      • 4.7.3.2. Clostridium Difficile
      • 4.7.3.3. Respiratory Virus
      • 4.7.3.4. TB and Drug-resistant TB
      • 4.7.3.5. Gonorrhea
      • 4.7.3.6. HPV
      • 4.7.3.7. HIV
      • 4.7.3.8. Hepatitis C
      • 4.7.3.9. Hepatitis B
      • 4.7.3.10. COVID-19
      • 4.7.3.11. Others
  • 4.8. Market Attractiveness Analysis: Application
  • 4.9. Global Infectious Disease In-Vitro Diagnostics Market Outlook: End User
    • 4.9.1. Introduction / Key Findings
    • 4.9.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2023
    • 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
      • 4.9.3.1. Point-of-care
      • 4.9.3.2. Central Laboratories
      • 4.9.3.3. Others
  • 4.10. Market Attractiveness Analysis: End User

5. Global Infectious Disease In-Vitro Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024 - 2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 6.2.1. By Country
    • 6.2.2. By Product Type
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 6.4.1. Instruments
    • 6.4.2. Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 6.5.1. Immunoassay
    • 6.5.2. Molecular Diagnostics
    • 6.5.3. Microbiology
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 6.6.1. MRSA
    • 6.6.2. Clostridium Difficile
    • 6.6.3. Respiratory Virus
    • 6.6.4. TB and Drug-resistant TB
    • 6.6.5. Gonorrhea
    • 6.6.6. HPV
    • 6.6.7. HIV
    • 6.6.8. Hepatitis C
    • 6.6.9. Hepatitis B
    • 6.6.10. COVID-19
    • 6.6.11. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 6.7.1. Point-of-care
    • 6.7.2. Central Laboratories
    • 6.7.3. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 7.2.1. By Country
    • 7.2.2. By Product Type
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 7.4.1. Instruments
    • 7.4.2. Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 7.5.1. Immunoassay
    • 7.5.2. Molecular Diagnostics
    • 7.5.3. Microbiology
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 7.6.1. MRSA
    • 7.6.2. Clostridium Difficile
    • 7.6.3. Respiratory Virus
    • 7.6.4. TB and Drug-resistant TB
    • 7.6.5. Gonorrhea
    • 7.6.6. HPV
    • 7.6.7. HIV
    • 7.6.8. Hepatitis C
    • 7.6.9. Hepatitis B
    • 7.6.10. COVID-19
    • 7.6.11. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 7.7.1. Point-of-care
    • 7.7.2. Central Laboratories
    • 7.7.3. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 8.2.1. By Country
    • 8.2.2. By Product Type
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 8.4.1. Instruments
    • 8.4.2. Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 8.5.1. Immunoassay
    • 8.5.2. Molecular Diagnostics
    • 8.5.3. Microbiology
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 8.6.1. MRSA
    • 8.6.2. Clostridium Difficile
    • 8.6.3. Respiratory Virus
    • 8.6.4. TB and Drug-resistant TB
    • 8.6.5. Gonorrhea
    • 8.6.6. HPV
    • 8.6.7. HIV
    • 8.6.8. Hepatitis C
    • 8.6.9. Hepatitis B
    • 8.6.10. COVID-19
    • 8.6.11. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 8.7.1. Point-of-care
    • 8.7.2. Central Laboratories
    • 8.7.3. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 9.2.1. By Country
    • 9.2.2. By Product Type
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 9.4.1. Instruments
    • 9.4.2. Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 9.5.1. Immunoassay
    • 9.5.2. Molecular Diagnostics
    • 9.5.3. Microbiology
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 9.6.1. MRSA
    • 9.6.2. Clostridium Difficile
    • 9.6.3. Respiratory Virus
    • 9.6.4. TB and Drug-resistant TB
    • 9.6.5. Gonorrhea
    • 9.6.6. HPV
    • 9.6.7. HIV
    • 9.6.8. Hepatitis C
    • 9.6.9. Hepatitis B
    • 9.6.10. COVID-19
    • 9.6.11. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 9.7.1. Point-of-care
    • 9.7.2. Central Laboratories
    • 9.7.3. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 10.2.1. By Country
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 10.4.1. Instruments
    • 10.4.2. Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 10.5.1. Immunoassay
    • 10.5.2. Molecular Diagnostics
    • 10.5.3. Microbiology
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 10.6.1. MRSA
    • 10.6.2. Clostridium Difficile
    • 10.6.3. Respiratory Virus
    • 10.6.4. TB and Drug-resistant TB
    • 10.6.5. Gonorrhea
    • 10.6.6. HPV
    • 10.6.7. HIV
    • 10.6.8. Hepatitis C
    • 10.6.9. Hepatitis B
    • 10.6.10. COVID-19
    • 10.6.11. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 10.7.1. Point-of-care
    • 10.7.2. Central Laboratories
    • 10.7.3. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Infectious Disease In-Vitro Diagnostics Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 11.2.1. By Country
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
    • 11.4.1. Instruments
    • 11.4.2. Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024 - 2031
    • 11.5.1. Immunoassay
    • 11.5.2. Molecular Diagnostics
    • 11.5.3. Microbiology
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024 - 2031
    • 11.6.1. MRSA
    • 11.6.2. Clostridium Difficile
    • 11.6.3. Respiratory Virus
    • 11.6.4. TB and Drug-resistant TB
    • 11.6.5. Gonorrhea
    • 11.6.6. HPV
    • 11.6.7. HIV
    • 11.6.8. Hepatitis C
    • 11.6.9. Hepatitis B
    • 11.6.10. COVID-19
    • 11.6.11. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
    • 11.7.1. Point-of-care
    • 11.7.2. Central Laboratories
    • 11.7.3. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Becton, Dickinson and Company
    • 12.3.3. bioMerieux SA
    • 12.3.4. F. Hoffmann-La Roche, Ltd.
    • 12.3.5. Hologic, Inc. (Gen Probe)
    • 12.3.6. Abbott
    • 12.3.7. Quidel Corporation
    • 12.3.8. Siemens Healthineers AG
    • 12.3.9. Bio-Rad Laboratories, Inc.
    • 12.3.10. Danaher
    • 12.3.11. OraSure Technologies, Inc.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations